On the stock market since 2007, it operates in the world of health and science. It has 213 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly above the class average — a step short of the very top.
Clearly below the class average.
The price isn’t cheap next to earnings — that’s why this grade sits in the middle.
Clearly below the class average.
Clearly below the class average.
Growth: Sales growth trails the sector average.
Price Momentum: The stock has lagged the market in recent months; investor interest is weak right now.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
The stock trades 56% below its peak. The market has trimmed its expectations for the company.
Sales run at $59.4M a year. A small number, but proof the product has real buyers.
There is $4.9M in the vault; even if every debt were paid off, $360K would remain.
Over the last 12 months, company executives reported 21 buys and 4 sells. Management buying with its own money is usually read as a good sign.
A loss of $1.2M against $59.4M in annual sales.
The growth engine is running at low revs right now. Report-card grade: 12/100.
Buyers haven’t stepped back in yet; the price hasn’t found its footing. Report-card grade: 26/100. For a turnaround signal, the stock first needs to close the gap with the market.
On our five-subject report card, CSBR sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: CSBR is a high-risk stock — not yet profitable, and its future rides on its product catching on.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.